论文部分内容阅读
目的探讨最大限度雄激素阻断(MAB)和间歇内分泌疗法(IHT)治疗晚期前列腺癌的疗效及副作用,为临床治疗晚期前列腺癌提供依据。方法 2006年1月至2010年1月我院共收治晚期前列腺癌患者90例,其中48例予比卡鲁胺联合手术去势的MAB治疗、42例予戈舍瑞林联合比卡鲁胺行IHT治疗。结果与MAB疗法相比,IHT疗法副作用小,治疗间歇期未加重肿瘤进展。结论 IHT疗法与MAB疗法治疗晚期前列腺癌的疗效无统计学差异,而IHT疗法安全、可行、副作用小,可作为雄激素依赖性晚期前列腺癌内分泌治疗的首选。
Objective To investigate the efficacy and side effects of maximal androgen blockade (MAB) and intermittent endocrine therapy (IHT) in the treatment of advanced prostate cancer and provide the basis for clinical treatment of advanced prostate cancer. Methods From January 2006 to January 2010, 90 patients with advanced prostate cancer were admitted to our hospital. Among them, 48 were treated with bicalutamide combined with surgical castration of MAB, and 42 were treated with goserelin combined with bicalutamide IHT treatment. Results Compared with MAB therapy, IHT had fewer side effects and did not exacerbate tumor progression during the intermission period. Conclusions There is no significant difference between IHT therapy and MAB therapy in the treatment of advanced prostate cancer. However, IHT therapy is safe, feasible and has few side effects and may be the first choice of endocrine therapy for androgen-dependent advanced prostate cancer.